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Macrophages are important for maintaining intestinal immune homeostasis. Here, we show that PPARb/d
(peroxisome proliferator-activated receptor b/d) directly regulates CD300a inmacrophages that express the
immunoreceptor tyrosine based-inhibitory motif (ITIM)-containing receptor. In mice lacking CD300a,
high-fat diet (HFD) causes chronic intestinal inflammationwith low numbers of intestinal lymph capillaries
and dramatically expanded mesenteric lymph nodes. As a result, these mice exhibit triglyceride
malabsorption and reduced body weight gain on HFD. Peritoneal macrophages from Cd300a2/2mice on
HFD are classically M1 activated. Activation of toll-like receptor 4 (TLR4)/MyD88 signaling by
lipopolysaccharide (LPS) results in prolonged IL-6 secretion in Cd300a2/2 macrophages. Bone marrow
transplantation confirmed that the phenotype originates from CD300a deficiency in leucocytes. These
results identify CD300a-mediated inhibitory signaling in macrophages as a critical regulator of intestinal
immune homeostasis.
T
he intestinal tract is the largest surface organ of the human body which is constantly exposed to dietary and
environmental antigens such as commensal bacteria. Therefore, the intestinal immune system has to
maintain homeostasis through the cooperation of various regulatory mechanisms that prevent overreaction
against beneficial flora and food antigens1,2. Dysregulation of intestinal immune responses is believed to cause
inflammatory bowel diseases (IBD), Crohn’s disease and ulcerative colitis, metabolic diseases such as obesity and
diabetes, and is also linked to autoimmune disease3,4. The largest number of macrophages in the body reside in
intestine and these cells are important for maintaining intestinal immune homeostasis5. This function is con-
trolled by positive and negative signals by activating and inhibitory cell surface immune receptors, respectively6.
In fact, lack of cell surface immune receptor Trem2, known to inhibit Myd88-mediated TLR signaling, has been
shown to increase in proinflammatory M1 marker cytokine production in macrophage and impaired wound
healing7.
The nuclear receptor PPARb/d has been shown to transcriptionally-regulate oxidative metabolism in muscle
and improve insulin sensitivity8,9. In macrophages, PPARb/d modulates resident macrophage polarization
through the Th2 cytokine signaling cascade10 and reduces atherogenic inflammation8. It has been indicated that
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PPARb/d agonist represses inflammatory gene expression by releas-
ing transcriptional co-repressor BCL-6 in macrophages11. In addi-
tion, PPARb/d has been supposed to attenuate chemokine receptor
signaling by the induction of RGS proteins, which is involved in the
termination of G protein signal12,13. However, the mechanisms
underpinning anti-inflammatory properties of PPARb/d have not
been fully understood.
In the current study, we performed comprehensive analysis of
PPARb/d regulated genes and genome-wide PPARb/d binding sites
to facilitate our understanding of the PPARb/d function in macro-
phages.We found that lack of CD300a, a novel PPARb/d target gene,
expression in leucocytes relieves the TLR4/Myd88 signaling which
leads to increase in proinflammatory cytokines in macrophages.
Results
PPARd activates Cd300a in macrophages. To investigate the
function of PPARb/d (NR1C2) in macrophages, we treated THP-1
macrophages with the high-affinity PPARb/d agonist GW501516
and performed a time course of global gene-expression analyses.
These were combined with ChIP-seq analyses using newly-
generated monoclonal antibodies against PPARb/d, as well as
antibodies against its heterodimer partner, RXRa14 (Supplementary
Fig. S1a–e). We also generated genome-wide maps of modification
sites for histone H3 lysine 4 mono- and tri-methylation (H3K4me1
and me3, respectively). Additionally, we identified binding sites for
the insulator binding protein, CCCTC-binding factor (CTCF).
GW501516 treatment induces the expression of 34 genes and
ChIP-seq analyses identified 28 of these genes as direct targets of
PPARb/d (Fig. 1a). These include known PPARb/d targets whose
gene products are involved in fatty acid metabolism, such as Pdk4,
Cpt1a, and Slc25A20 (Supplementary Fig. S1f). Interestingly,
PPARb/d also directly regulates genes encoding molecules that
potentially inhibit signaling of the immunoreceptor tyrosine-based
activation motif (ITAM) (Cd300a, Sh3bp5, and Dscr1) (Fig. 1a). In
fact, Cd300a was one of the most robustly induced genes.
CD300a is an inhibitory immunoreceptor that fine tunes innate
immune cell activity through an ITIM-mediated inhibitory signal
(Fig. 1b)15. It is preferentially expressed on cell surface of myeloid-
lineage cells including macrophages, dendritic cells and mast cells16.
In macrophages17,18 and in mast cells18, CD300a inhibits the TLR4 (a
receptor for LPS and fatty acids) signaling pathway, leading to the
inhibition of the innate immune system19. However, the physio-
logical function of CD300a in macrophages is not fully understood
yet.
ChIP-seq analysis revealed the binding of PPARb/d and RXRa to
sites downstream of exon 4 in Cd300a. These sites were flanked by
H3K4me1 modifications (Fig. 1c, Supplementary Fig. S2a). Because
H3K4me1 is a marker for histone chromatin modification of enhan-
cer regions, these results indicate that Cd300a gene expression is
regulated directly by the PPARd/RXRa heterodimer. In agreement
with this result, we identified a potential PPAR responsive element
(TGCCCT T TCACCT/C; PPRE) in this intron (Fig. 1d). This PPRE
is conserved among mouse, rat, and human and was able to mediate
PPARb/d dependent transactivation. Cotransfection of the luciferase
reporter vector with a PPARb/d and RXRa expression vector in-
creased luciferase activity, and this was further enhanced by the
addition of GW501516 (Fig. 1e). Moreover, GW501516 treatment
consistently increased the abundance of Cd300a mRNA in THP-1
macrophages in a time- and dose-dependent manner (Fig. 1f,g). This
induction was abrogated by shRNA-mediated knock down of
PPARb/d (Supplementary Fig. S2b,c). GW501516-mediated Cd300a
gene induction was observed in peritoneal macrophages from wild-
type mice but not from PPARb/d-null mice (Fig. 1h). Another
PPARb/d specific agonist, L-165041, also induced Cd300a mRNA
(Supplementary Fig. S2d). Taken together these data identify Cd300a
as a bona fide target of PPARb/d.
Cd300a deficiency causes gut inflammation under HFD feeding.
To gain insights into the biological role of CD300a, we generated
CD300a-null mice as described elsewhere18. We fed these animals a
diet rich in lard-based SFAs (HFD) (Supplementary Table S1a).
Histological examination revealed enhanced immune staining of
FA/111(CD68) and F4/801 macrophages and Thy1.21 T cells in
the intestine and colon of Cd300a2/2 mice fed HFD (Fig. 2a,b,
Supplementary Fig. S3). Oil red O (ORO) staining revealed
marked lipid accumulation in the intestinal epithelium of these
mice (Fig. 2c,d). Lymphatic capillaries were very narrow and
hardly visible in the intestine from these Cd300a2/2 mice fed
HFD (Fig. 2e,f). Furthermore, the mesenteric lymph nodes
(MLNs) were markedly expanded with accumulation of lipid-laden
macrophages and foam cell formation indicating inflammation in
MLNs (Fig. 2g–l). In addition, the length of small intestine and colon
of Cd300a2/2 mice are shortened by HFD feeding (Fig. 2m,n).
Transcriptome analyses of intestine showed up-regulation of the
expression of chemokine and pro-inflammatory genes (FCcr1,
FCcr3, Cxcl4, Cx3cr1, and Il6), adhesion molecules (Vcam1,
Esam1, and Pecam1) and the macrophage marker Cd68 in the
same 18-week-old Cd300a2/2 mice on HFD. These data suggest
that macrophages are responsible for this chronic intestinal
inflammation (Fig. 2o).
Cd300a2/2 mice shows impaired lipid absorption under HFD
feeding. Since dietary lipids are absorbed from the intestine by the
lymph capillaries, we next examined the fat absorption of HFD fed
Cd300a2/2 mice. Acute fat-loading demonstrated that triglyceride
(TG) levels in Cd300a2/2 mice remained low in contrast to the
Cd300a1/1 mice, and no peak in serum TG levels at 2 h occurred
(Fig. 3a,b). Consistently, serum lipid content, including non-
esterified free fatty acid (NEFA) and TG, is significantly reduced in
the same Cd300a2/2 mice on HFD (Fig. 3c–e). HPLC analysis of
plasma lipoproteins showed a substantial reduction in chylomicron
and very low-density lipoprotein (VLDL) TG levels in HFD-fed
Cd300a2/2 mice (Fig. 3f). Food intake, oxygen consumption, and
rectal temperature showed no significant differences between
Cd300a1/1 and Cd300a2/2 mice (Fig. 3g–k). RQ value is
significantly higher in HFD fed Cd300a2/2 mice than that of
Cd300a1/1 (P , 0.05) indicating lower utilization of lipid as an
energy source (Fig. 3j). These observations indicated that the chronic
intestinal inflammation associated with lymph capillary obstructions
led to impaired intestinal lipid absorption of HFD fed Cd300a2/2
mice. As a result of impaired lipid absorption, Cd300a2/2 mice
gained less body weight relative to Cd300a1/1 mice on HFD
(Fig. 2p, Supplementary Fig. S4a–e). Feeding palm oil-based high
saturated fat diets resulted in a similar phenotype to the lard-based
HFD (Supplementary Table S1b, Supplementary Fig. S5a–c).
Hematopoietic deficiency of CD300a augments TLR4 mediated
IL6 production and exacerbates intestinal inflammation. To
examine the influence of CD300a deficiency on macrophages, we
used oligonucleotide microarray and qPCR to examine classically-
activated pro-inflammatory M1 and alternatively-activated anti-
inflammatory M2 macrophage marker gene expressions in
peritoneal macrophages. This analysis revealed that macrophages
from Cd300a1/1 mice on HFD resemble alternatively-activated
anti-inflammatory M2 macrophages. They express a number of
M2 markers including Cd163, Mrc1, Folr2, Igf1, Clec4a320–22,
whereas those from Cd300a2/2 mice expressed classically-
activated M1 markers including Il1a, Il6, Ccl3, Ccl4, Serpine1,
Ptgs2, Tnfa20,23 (Fig. 4a,b, Supplementary Fig. S6). Lyve-124, is
considered another M2-macrophage related gene21,25 whose
product is pivotal in lymphatic vessel development. Intriguingly,
Lyve-1 was highly induced upon HFD in Cd300a1/1 mice and
this was not observed in Cd300a2/2 mice (Fig. 4a,b). These data
suggested thatCd300a2/2micemay have a defect in preventing the
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Figure 1 | Cd300a is a direct target of PPARd. (a) Heat map: Color denotes the GW501516-induced changes in THP-1 macrophages. (b) Schematic
diagram of CD300a. (c) Histogram of ChIP fragments. (d,e) PPRE present in intron 4 of Cd300a gene is conserved among species (d) and can mediate
Cd300a induction by PPARb/d (e). Error bars show s.e.m. **P, 0.01. (f,g) Time course ofCd300a expression in THP-1 cells exposed toGW501516/PMA
(f) and dose response in THP-1 macrophages treated with GW501516 (g). (h) Cd300a induction by GW501516 is blunted in peritoneal macrophages
from PPARb/d-null mice (n 5 3). Error bars show s.e.m. *P , 0.05; **P , 0.01 compared with DMSO treatment.
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appropriate responses seen in chronic inflammatory and autoim-
mune diseases.
Because HFD induces activation of TLR4 signaling pathway and
causes low-grade intestinal inflammation26, we asked whether lack of
CD300a expression relieves the inhibition of TLR4 signaling and in
turn lead to an increase in pro inflammatory cytokine production in
macrophages. To examine this hypothesis, we treated peritoneal
macrophages from Cd300a1/1 and 2/2 mice with LPS for 3 h to
trigger the TLR4 signaling pathway27 and subsequently cultured
them in LPS-minus media (Fig. 4c). LPS treatment led to a 60%
reduction of Cd300 expression (Fig. 4d), consistent with results pre-
vious reported in monocytes28, and induced Il6 expression (Fig. 4e).
Lack of Cd300a in macrophages resulted in 2.5-fold higher express-
ion of Il6 upon LPS induction (Fig. 4e). Furthermore, while IL-6
secretion from Cd300a1/1 macrophages continued at similar levels
during 24 h incubation after removal of LPS, IL-6 secretion from
Cd300a2/2 macrophages did not cease even after 24 h in the
absence of LPS (Fig. 4f). These data together with our previous data18
indicate that CD300a is pivotal in preventing or terminating TLR4-
triggered Il6 expression and IL-6 secretion (Fig. 4g).
To specify whether HFD-induced intestinal inflammation in
Cd300a2/2 mice originates from malfunction of intestinal resident
macrophages, we adoptively transferred CD300a-deficient bone
marrow into lethally-irradiated wild-type mice (male C57BL/6J
strain). After reconstitution for 4 weeks, age-matched cohorts were
placed on HFD or NCD for 15 weeks (Fig. 4h). qPCR analysis con-
firmed.84% replacement of wild-typemarrow byCd300a2/2 cells
(Fig. 4i). Reconstitution of wild-type mice with Cd300a2/2 bone
marrow led to enhanced macrophage infiltration in the intestine of
BMT-Cd300a2/2 mice (Fig. 4j), resulting in resistance to body
weight gain on HFD (Fig. 4h) with no apparent changes in food
intake (Supplementary Fig. S7a). This is similar to results observed
in Cd300a2/2 mice on a BALB/c genetic background. Serum lipid
content and the mass of fat depots in adipose tissues were reduced in
BMT-Cd300a2/2 mice compared to BMT-Cd300a1/1 mice on
HFD (Supplementary Fig. S7b–g). Conversely, reconstitution of
Cd300a2/2mice with wild-type bonemarrow significantly restored
weight gain on HFD (Supplementary Fig. S8a–d).
Discussion
The small intestine is the organ that digests and absorbs dietary
nutrients such as lipids. It is also exposed to a host antigens from
the diet and from commensal bacterial. Fatty acids are a constituent
of lipid nutrients and also serve as signaling molecules that influence
biological processes. Fatty acids are also part of the lipid moiety of
LPS and play an important role in activation of TLR4. Fatty acids
thereby induce NF-kB target genes such as cyclooxygenase 2 (Cox2
(ptgs2)), Tnfa, and Il6 in macrophages29,30. By contrast, PPARb/d
regulates expression of its target genes as a fatty acid sensor in
macrophages31.
In the current study, we show that activation of PPARb/d induced
the CD300a immunoreceptor. HFD feeding significantly induced
intestinal inflammation in the Cd300a2/2 and BMT-Cd300a2/2
mice (Fig. 2,4). PPARb/d target Cd300a was induced in HFD fed
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Cd300a1/1 mice macrophages (Fig. 2m,4b). In parallel, expression
of M2 macrophage marker genes was also increased. By contrast, in
macrophages of Cd300a2/2 mice fed HFD, pro-inflammatory Il6,
ptgs2 (whose gene product is COX2), and Tnfa expression were
increased (Figure 4a,b). These are all M1 macrophage markers. In
cultured macrophages, LPS treatment led to the reduction of Cd300a
expression (Fig. 4d). We also found that Il6 expression and secretion
by LPS pretreatment were enhanced in the Cd300a2/2 macro-
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phages (Fig. 4e,4f). Based on the previous literature, we postulate that
this is mediated by the TLR4/Myd88 signaling pathway17,18.
However, we do not exclude the possibility that other PPARb/d
target molecules inhibit ITAM signaling (e.g. SH3BP5 and DSCR1)
or that an anti-inflammatory co-repressor BCL-611 suppresses
inflammation, PPARb/d-CD300a axis suppressed inflammatory
cytokine IL6 production induced by TLR4/Myd88 signaling by diet-
ary antigens. Based on these finding we propose that CD300a, a novel
PPARb/d target gene in macrophages, maintains intestinal immune
response. In wild type mice, HFD-derived fatty acids can activate the
TLR4/Myd88 pathway, but the PPARb/d-CD300a pathway inhibits
TLR4/Myd88 pathway; therefore IL6 production is suppressed. In
Cd300a2/2 mice, HFD-derived fatty acids activate only the TLR4/
Myd88 pathway and IL6 production proceeds as illustrated in
Figure 4g.
Dysregulation of the intestinal innate immune response is linked
to metabolic disease32 and type 1 diabetes (T1D)3. Interestingly,
Cd300a2/2 mice exhibit higher blood glucose levels with reduced
serum insulin levels in Cd300a2/2 mice and BMT-Cd300a2/2
mice compared to controls (Supplementary Fig. S9a, S7h,i, respect-
ively) despite of impaired lipid absorption. Glucose tolerance tests
further showed that glucose-induced increases in serum insulin
levels were significantly reduced in Cd300a2/2 mice on HFD
(Supplementary Fig. S9b). It has been demonstrated that pancreatic
islet-infiltrating lymphocytes express a4b7-integrin, which is a hom-
ing receptor to the gut mucosa33. In addition, it is well known that
endocrine and exocrine cells of the pancreas are derived from a
common set of epithelial cells from early gut endoderm. These obser-
vation suggested that pancreatic b-cells are affected by the homing
lymphocytes during intestinal inflammation. Therefore, the PPARb/
d-CD300a axis may prevent food antigen-induced intestinal inflam-
mation andmetabolic diseases such as insulin resistance, atheroscler-
osis, and T1D.
These results suggest a novel mechanism through which PPARb/d
activation leads to immuno-inhibitory receptor signaling to suppress
chronic inflammation. The ability of PPARb/d to integrate metabol-
ism and the innate immune system suggests that PPARb/d activation
and subsequent CD300a induction could be a new therapeutic strat-
egy to treat enteropathic diseases such as inflammatory-bowel-
disease-like disease including Celiac disease34,35. In addition to our
previous work which identified PPARb/d as a therapeutic target for
the metabolic syndrome9, PPARb/d activation and its key role in
intestinal immune modulation may also prove effective for the man-
agement of T1D.
Methods
Themethods used in this study are described in detail in Supplementary Information.
Chemical reagents. Selective high affinity agonists of PPARb/d GW50151636 and
fenofibric acid were synthesized as described previously9. L-165041 was purchased
from Sigma-Aldrich, rosiglitazone (BRL 49653) fromCayman Chemical, phorbol 12-
myristate 13-acetate (PMA) from Wako Pure Chemical Industries.
Antibodies. Mouse monoclonal IgG-Y9705 against human PPARb/d and IgG-
K8508 against human RXRa were raised in our laboratory by immunizing separate
mice with recombinant baculovirus displaying gp64-fusion proteins containing
amino acids 2–41 of human PPARb/d and 2–133 of human RXRa, respectively37.
Other antibodies were obtained from the following sources: rabbit polyclonal anti-
histone H3 trimethyl K4 (ab8580) from Abcam; polyclonal rabbit anti-CTCF (07-
729) from Millipore; mouse monoclonal anti-Nucleoporin p62 (610497) and rat
monoclonal anti-CD90.2 (550543, Thy-1.2) from BDTransduction laboratories; goat
polyclonal anti-podoplanin (A-18) (sc-23564) from Santa Cruz biotechnology; rat
monoclonal anti-CD68 (clone FA/11,MCA1957), anti-B220 (MCA1258G), and anti-
F4/80 (MCA497GA) from AbD Serotec. Mouse monoclonal anti-histone H3
monomethyl K4 (clone CMA302) was a kind gift from Dr. H. Kimura.
Histology.Haematoxylin and eosin (H&E) staining of sections was performed using
standard protocols (Supplementary Information). For detection of macrophages,
immunohistochemistry was performed using antibody against CD68 or F4/80 and,
for detection of lymph vessels, antibody against podoplanin was used. For Oil red O
staining, frozen sections embedded in OCT were air-dried and fixed in formalin
followed by brief washingwith water and rinsing with 60% isopropanol. Sections were
immersed in freshly prepared Oil Red O working solution for 15 minutes followed by
rinses with 60% isopropanol. Haematoxylin nuclei staining was performed
subsequently.
Cells. Human monocytic leukemia THP-1 cells were purchased from ATCC and
maintained in RPMI 1640 medium (Invitrogen) supplemented with 10% heat-
inactivated fetal bovine serum (FBS) containing 100 Uml21 penicillin and 100 mg
ml21 streptomycin (Gibco) (medium A) at 37uC in 5% CO2. THP-1 monocytes were
differentiated into macrophages with 10 nM PMA for 24 h as previously described.
Raw 264.7 cells, a line of murine macrophage-like cells, were purchased from ATCC
and maintained in DMEM containing 10% FBS, 100 Uml21 penicillin and 100 mg
ml21 streptomycin (Gibco) at 37uC and 5% CO2.
Peritoneal macrophage cells from wild-type C57BL/6J (CLEA, Japan), CD300a-
null, or PPARb/d-null mice38 were prepared as follows: mice were sacrificed and
resident peritoneal cells were harvested by lavage with sterile phosphate buffered
saline (PBS) (pH 7.4). After centrifugation at 190 3 g for 5 min, cells were re-
suspended in medium A and plated in 6-well plates and incubated for 2 h at 37uC in
5%CO2 to allow cells to attach to plates. Plates were subsequently washed with PBS to
remove non-adherent cells. The resulting attached cells were used in experiments as
peritoneal macrophages.
For LPS stimulation, macrophages cells were plated in 12-well plates in medium A
on day 0 and, on day 1, cells were washed with PBS, cultured in RPMI1640 containing
0.1% FBS supplemented with 100 Uml21 penicillin and 100 mg ml21 streptomycin
(Gibco) (mediumB) for 4 h, then switched tomediumB in the absence or presence of
200 ng/ml of LPS. After 3 h incubation, LPS were washed out with PBS 3 times, and
cells were refed with medium B for the indicated period of time as described in the
legend to Fig. 4c. IL-6 levels in the culture medium were determined by Mouse IL-6
Quantikine ELISAKit (R &D systems) and normalized to total cellular protein levels.
Transcriptome microarray analysis. For genome-wide transcription analysis,
GeneChip Human Genome U133 Plus 2.0 Array or GeneChip Mouse Genome 430
2.0 array were used as described previously9,14 (Supplementary Information).
ChIP-seq and ChIP-qPCR analysis. Chromatin immunoprecipitation (ChIP) was
performed as described14 (Supplementary Information). Briefly, THP-1 cells after 24-
h treatment with 10 nMPMA in the absence or presence of 100 nMGW501516 were
cross-linked with 1% formaldehyde for 10 min at room temperature and chromatin
DNA was sheared by sonication. The resultant was immunoprecipitated with the
indicated antibodies overnight at 4uC14. After washing and elution, the protein-DNA
complexes were reversed by heating at 65uC overnight. Immunoprecipitated DNA
was purified by using QIAquick spin columns (Qiagen). ChIP sequencing (ChIP-seq)
sample preparation was performed according to the manufacture’s instructions as
described elsewhere (Ilumina)14. ChIP samples were also analyzed by gene-specific
quantitative real time PCR.
Quantitative real-time PCR (qPCR). The qPCR method has been described9
(Supplementary Information). All primer sequences used in this paper are available
on request.
Lentiviral shRNA knockdown. To deplete cellular PPARb/d, MISSION Lentiviral
Packaging Mix and the lentiviral shRNA transfer vectors (Sigma-Aldrich) were co-
transfected into 293FT cells using Lipofectamine 2000 (Invitrogen). Lentiviral
particles carrying shRNAs targeting human PPARb/d were used to infect THP-1
cells.
Construction of the promoter reporter gene. pCD300a(806) is pGL3-Promoter-
based luciferase reporter gene vector that harbors sequences from human CD300a
intron 4 spanning positions from 69,986,265 to 69,987,070 of chromosome 17. To
construct this plasmid, the corresponding region was amplified by PCR and cloned
into pGL3-Promoter vector (Promega). Base substitution and deletion mutants were
generated in pCD300a(806) with the QuikChange II site-directed mutagenesis kit
(Stratagene).
Luciferase reporter assay. Raw264.7 cells were transfected with the indicated
reporter together with expression plasmids (pCMV-hPPARd and pCMV-hRXRa)9
together with renilla luciferase plasmids (pRL-CMV) using Lipofectamine 2000
(Invitrogen) and treated with either with 100 nM GW501516 or vehicle (DMSO)
24 h after transfection14. After overnight treatment, cells were lysed in lysis buffer
(Promega) and analyzed using the Dual-LuciferaseH Reporter Assay System
(Promega). Firefly luciferase signal was normalized to renilla luciferase signal. All
luciferase assay data represent the mean 6 s.e.m of triplicate samples.
Animal experiments. Cd300a-null (BALB/cAJcl (BALB/c) back ground)18 and
PPARb/d-null38 mice were generated as described elsewhere. All animals were housed
in a temperature-controlled (24uC) facility with 12-h light/dark cycles (08:00 to 20:00
light) and allowed free access to water and NCD (CE-2; CLEA Japan) or HFD
described in Supplementary Table 1. Food intake and body weights were monitored
twice a week and core body temperature was measured using a rectal thermometer
probe at 13:00. All mice were sacrificed at 13:00 and blood was taken from inferior
vena cava. Serum TG, cholesterol, NEFA, and glucose levels were determined by
Triglyceride E-Test Wako, Cholesterol E-Test Wako, NEFA C-Test Wako, Glucose
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C-II TestWako (Wako Pure Chemical Industries), respectively. Serum insulin, leptin
and adiponectin levels were determined by ELISA using an immunoassay kit
(Shibayagi, Gunma, Japan). For bone marrow transplantation, total bone marrow
hematopoietic progenitor donor cells harvested from Cd300a2/2 or wild-type mice
on CBL/6JJcl (C57BL6/J) background (backcrossed into C57BL6/J for 8 generations)
were transplanted via orbital vein injection into lethally irradiated wild-type or
Cd300a2/2 mice, respectively, on C57BL6/J background (1100 rads; Cobalt-60
source) with a minimum cell dose of 106 mononuclear cells per mouse. Transplanted
mice were housed in microisolator cages for 4 weeks prior to challenge with HFD. All
data are presented as mean 6 s.e.m. All mouse protocols were approved by the
Animal Care and Use Committee of the University of Tokyo and Tsukuba.
Resting metabolic rate measurement. Seven to eleven weeks after HFD feeding was
started, oxygen consumption was measured using open circuit indirect calorimetry
(Model MK-5000, Muromachikikai, Tokyo). The chamber volume was 720 ml,
airflow to the chamber was 500 ml/min, samples were taken every 3 min and a
standard gas reference was taken every 30 min. Mice were kept in the metabolic
chamber and acclimated for 1 day.
Acute fat loading test.Acute fat loading test were performed in 12 week old HFD fed
Cd300a1/1 and Cd300a2/2 mice. Mice were orally administered 3 ml/kg BW of
olive oil (Sigma, O1514) and blood samples were drawn from the tail vein at 0, 1, 2, 4,
and 6 h after administration. Serum triglyceride and NEFA were measured.
HPLC analysis. An improved high resolution HPLC analysis of plasma lipoprotein
was performed as described previously39. 20 ml of plasma was mixed with 180 ml of
saline and applied to four columns of TSK Gel Lipopack XL (Tosoh, Tokyo)
connected in tandem. The detection of cholesterol and triglycerides in the post-
column effluent was conducted by a simultaneous profiling system for lipoprotein
cholesterol, triglyceride, and free glycerol in an on-line system.
Statistical analyses. All data are presented as mean 6 s.e.m. The homogeneity in
variance was evaluated by Bartlett test followed by parametric or non-parametric
Dunnett’s multiple comparison test (one-side). The Student’s or Aspin-Welch t-test
(one-side) was used to compare the data between the control and treated groups. *P
, 0.05, **P , 0.01.
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